^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Angiogenesis inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: a multicenter retrospective study
Published date:
07/24/2023
Excerpt:
For ERBB2-mutant patients, the mPFS was 5.9 months, and Chemo+Immuno and Chemo+Antiangio both achieved longer mPFS than TKI (12.9 vs 2.9 months, HR: 0.15, 95%CI: 0.03-0.68, P=0.005; 7.1 vs 2.9 months, HR: 0.50, 95%CI: 0.29-0.88, P=0.009, respectively).
Secondary therapy:
Chemotherapy
DOI:
https://doi.org/10.1016/j.lungcan.2023.107315
